Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 195

1.

Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma.

Cipollini M, Figlioli G, Maccari G, Garritano S, De Santi C, Melaiu O, Barone E, Bambi F, Ermini S, Pellegrini G, Cristaudo A, Foddis R, Bonotti A, Romei C, Vivaldi A, Agate L, Molinari E, Barale R, Forsti A, Hemminki K, Elisei R, Gemignani F, Landi S.

DNA Repair (Amst). 2016 May;41:27-31. doi: 10.1016/j.dnarep.2016.03.011. Epub 2016 Mar 31.

PMID:
27062014
2.

The importance of p53 pathway genetics in inherited and somatic cancer genomes.

Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, Zeron-Medina J, Castro-Giner F, Tomlinson IP, Goding CR, Cygan KJ, Fairbrother WG, Thomas LF, Sætrom P, Gemignani F, Landi S, Schuster-Böckler B, Bell DA, Bond GL.

Nat Rev Cancer. 2016 Mar 24;16(4):251-65. doi: 10.1038/nrc.2016.15.

PMID:
27009395
3.

Runs of homozygosity and inbreeding in thyroid cancer.

Thomsen H, Chen B, Figlioli G, Elisei R, Romei C, Cipollini M, Cristaudo A, Bambi F, Hoffmann P, Herms S, Landi S, Hemminki K, Gemignani F, Försti A.

BMC Cancer. 2016 Mar 16;16(1):227. doi: 10.1186/s12885-016-2264-7.

4.

Targeting hypoxic response for cancer therapy.

Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S.

Oncotarget. 2016 Feb 7. doi: 10.18632/oncotarget.7229. [Epub ahead of print]

5.

A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma.

Figlioli G, Elisei R, Romei C, Melaiu O, Cipollini M, Bambi F, Chen B, Köhler A, Cristaudo A, Hemminki K, Gemignani F, Försti A, Landi S.

Cancer Epidemiol Biomarkers Prev. 2016 Feb 3. [Epub ahead of print]

PMID:
26843521
6.

Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma.

Pellé L, Cipollini M, Tremmel R, Romei C, Figlioli G, Gemignani F, Melaiu O, De Santi C, Barone E, Elisei R, Seiser E, Innocenti F, Zanger UM, Landi S.

Arch Toxicol. 2016 Jan 19. [Epub ahead of print]

PMID:
26783003
7.

Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome.

Naccarati A, Rosa F, Vymetalkova V, Barone E, Jiraskova K, Di Gaetano C, Novotny J, Levy M, Vodickova L, Gemignani F, Buchler T, Landi S, Vodicka P, Pardini B.

Oncotarget. 2015 Dec 31. doi: 10.18632/oncotarget.6804. [Epub ahead of print]

8.

Characterization of the painful restless legs syndrome.

Gemignani F, Parrino L.

Sleep Med. 2015 Nov;16(11):1449. doi: 10.1016/j.sleep.2015.08.017. Epub 2015 Sep 5. No abstract available.

PMID:
26459676
9.

Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease.

Piscosquito G, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Manganelli F, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laurà M, Calabrese D, Hughes RA, Radice D, Solari A, Pareyson D; CMT-TRIAAL Group; CMT-TRAUK Group.

Eur J Neurol. 2015 Dec;22(12):1556-63. doi: 10.1111/ene.12783. Epub 2015 Jul 31.

PMID:
26227902
10.

Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.

Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Cayuela AJ, Wętek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J.

Endocr Relat Cancer. 2015 Aug;22(4):545-59. doi: 10.1530/ERC-15-0029. Epub 2015 Jun 22.

PMID:
26099684
11.

Expression status of candidate genes in mesothelioma tissues and cell lines.

Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S.

Mutat Res. 2015 Jan;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13.

PMID:
25771974
12.

Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk.

Figlioli G, Chen B, Elisei R, Romei C, Campo C, Cipollini M, Cristaudo A, Bambi F, Paolicchi E, Hoffmann P, Herms S, Kalemba M, Kula D, Pastor S, Marcos R, Velázquez A, Jarząb B, Landi S, Hemminki K, Gemignani F, Försti A.

Sci Rep. 2015 Mar 10;5:8922. doi: 10.1038/srep08922.

13.

A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.

Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddis R, Cristaudo A, Landi S.

J Thorac Oncol. 2014 Nov;9(11):1662-8. doi: 10.1097/JTO.0000000000000322.

14.

Fibromyalgia syndrome and small-fiber neuropathy.

Gemignani F.

Ann Neurol. 2014 Dec;76(6):916. doi: 10.1002/ana.24269. Epub 2014 Nov 17. No abstract available.

PMID:
25186210
15.

Fibromyalgia syndrome and small-fiber neuropathy: comment on the article by Caro and Winter.

Gemignani F.

Arthritis Rheumatol. 2014 Dec;66(12):3526-7. doi: 10.1002/art.38812. No abstract available.

16.

MicroRNA binding site polymorphisms as biomarkers in cancer management and research.

Cipollini M, Landi S, Gemignani F.

Pharmgenomics Pers Med. 2014 Jul 23;7:173-91. doi: 10.2147/PGPM.S61693. eCollection 2014. Review.

17.

Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.

Mannil M, Solari A, Leha A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B, Walter MC, Rautenstrauss B, Schnizer TJ, Schenone A, Seeman P, Kadian C, Schreiber O, Angarita NG, Fabrizi GM, Gemignani F, Padua L, Santoro L, Quattrone A, Vita G, Calabrese D; CMT-TRIAAL/CMT-TRAUK Group, Young P, Laurà M, Haberlová J, Mazanec R, Paulus W, Beissbarth T, Shy ME, Reilly MM, Pareyson D, Sereda MW.

Neuromuscul Disord. 2014 Nov;24(11):1003-17. doi: 10.1016/j.nmd.2014.06.431. Epub 2014 Jun 19.

PMID:
25085517
18.

Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.

Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, García-Sanz R, Buda G, Gemignani F, Ríos R, Vangsted AJ, Dumontet C, Martínez-López J, Moreno MJ, Stępień A, Wątek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudziński M, Weinhold N, Reis RM, Canzian F.

Int J Cancer. 2015 Mar 1;136(5):E351-8. doi: 10.1002/ijc.29101. Epub 2014 Aug 6.

19.

Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk.

Figlioli G, Köhler A, Chen B, Elisei R, Romei C, Cipollini M, Cristaudo A, Bambi F, Paolicchi E, Hoffmann P, Herms S, Kalemba M, Kula D, Pastor S, Marcos R, Velázquez A, Jarząb B, Landi S, Hemminki K, Försti A, Gemignani F.

J Clin Endocrinol Metab. 2014 Oct;99(10):E2084-92. doi: 10.1210/jc.2014-1734. Epub 2014 Jul 16.

PMID:
25029422
20.

Is overwork weakness relevant in Charcot-Marie-Tooth disease?

Piscosquito G, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laurà M, Calabrese D, Hughes RA, Radice D, Solari A, Pareyson D; CMT-TRIAAL & CMT-TRAUK Group.

J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1354-8. doi: 10.1136/jnnp-2014-307598. Epub 2014 Mar 21.

PMID:
24659795
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk